• For inclusion in the study, patient should fulfill the following criteria:

• Female patient ≥ 18 years of age.

• Signed informed consent and ability to comply with treatment and follow-up.

• Patient with newly diagnosed, a. Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer, b. Histologically confirmed (based on local histopathological findings):

• • high grade serous or

⁃ high grade endometrioid (grade 2 and 3) or

⁃ other epithelial non mucinous and non-clear cell ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation, c. At an advanced stage: FIGO stage IIIA to IIIC of the 2018 FIGO classification.

• Patient having undergone frontline, complete cytoreductive surgery (i.e. no visible residual disease): The patient will be considered eligible once the ESGO Quality Assurance in Ovarian Cancer Surgery will have been filled out and validated

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

• Patient must have received one cycle of carboplatin AUC 5-6 + paclitaxel 175 mg/m²

• Patient must have started cycle 1 chemotherapy no later than 6 weeks after surgery.

• Patient must have a thorax-abdomen-pelvis CT scan between surgery and Cycle 1, with no evidence of disease.

• Patient eligible for first line platinum-taxane chemotherapy:

⁃ Patient eligible for bevacizumab treatment in combination with chemotherapy and in maintenance. It must be started at the second chemotherapy cycle and be administered at a dose of 15mg/kg every 3 weeks up to a total of 15 months.

⁃ Patient must have normal organ and bone marrow function before first cycle of chemotherapy:

∙ Hemoglobin ≥ 9.0 g/dL.

‣ Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.

‣ Platelet count ≥ 100 x 109/L.

‣ Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).

‣ Aspartate aminotransferase/Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤ 2.5 x ULN.

‣ Serum creatinine ≤ 1. 5 x institutional ULN and GFR \> 50 mL/min, by using an exact measure (ie. Iohexol clearance) or the most appropriate formula (Jeliffe, Cockroft Gault, MDRD, CKD-EPI) to the investigator's discretion.

‣ Patient not receiving anticoagulant medication who has an International Normalized Ratio (INR) ≥1.5 and an Activated ProThrombin Time (aPTT) ≥1.5 x ULN.

⁃ The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or APTT is within therapeutic limits (according to site medical standard). If the patient is on oral anticoagulants, dose has to be stable for at least two weeks at the time of randomization.

⁃ Urine dipstick for proteinuria \< 2+. If urine dipstick is ≥2+, 24-hour proteinuria must be \<1 g.

⁃ Normal blood pressure or adequately treated and controlled hypertension (systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg).

⁃ Formalin fixed paraffin embedded (FFPE) tumor sample from the primary cancer must be available for local BRCA testing and if possible HRD testing (optional).

⁃ For countries where this will apply to: a subject will be eligible for randomization in this study only if either affiliated to, or a beneficiary of a social security category.